Open figure viewer
Abstract
Introduction: This study aimed to explore the relationships between C-reactive protein-triglyceride-glucose index (CTI), a comprehensive indicator of the triglyceride-glucose (TyG) index and C-reactive protein (CRP), and the risk of overactive bladder (OAB). Methods: A total of 6,014 participants from the US National Health and Nutrition Examination Survey (NHANES) were included for cross-sectional study from 2005 to 2010. The presence of OAB was defined as the Overactive Bladder Syndrome Symptom Score (OABSS) reaching 3 points or above. After taking into account the covariates, multivariable logistic regression was employed to examine the association between CTI and OAB, and a multiple imputation technique was applied. Restricted cubic spline (RCS) analyze was used to explore dose-response relationships and interaction effects, respectively. Results: OAB and nocturia were associated with higher CTI levels and prevalence of hypertension, diabetes, and dyslipidemia. In fully adjusted models, the highest CTI quartile was significantly associated with increased risks of OAB (OR: 1.26, 95% CI: 1.13–1.40, p < 0.001), nocturia (OR: 1.38, 95% CI: 1.26–1.51, p < 0.001) with consistent validated by multiple imputation. The RCS analysis showed the risk of incident OAB rose progressively as CTI increased, with a clear linear pattern. We further found that body mass index (BMI) acts as an indirect mediator in the relationship between CTI and both OAB and nocturia via mediation analysis. Conclusion: CTI is significantly associated with OAB and its nocturia subtypes, which is partially mediated by BMI. CTI own potential value for risk characterization and for identifying individuals with OAB.
References
1.
Abrams
P
, Cardozo
L
, Fall
M
, Griffiths
D
, Rosier
P
, Ulmsten
U
, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society
. Urology
. 2003
;61
(1
):37
–49
. 2.
White
N
, Iglesia
CB
. Overactive bladder
. Obstet Gynecol Clin North Am
. 2016
;43
(1
):59
–68
. 3.
Zhang
L
, Cai
N
, Mo
L
, Tian
X
, Liu
H
, Yu
B
. Global prevalence of overactive bladder: a systematic review and meta-analysis
. Int Urogynecol J
. 2025
;36
(8
):1547
–66
. 4.
Coyne
KS
, Sexton
CC
, Irwin
DE
, Kopp
ZS
, Kelleher
CJ
, Milsom
I
. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study
. BJU Int
. 2008
;101
(11
):1388
–95
. 5.
Irwin
DE
, Milsom
I
, Hunskaar
S
, Reilly
K
, Kopp
Z
, Herschorn
S
, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study
. Eur Urol
. 2006
;50
(6
):1306
–15
. 6.
Ruff
L
, Bagshaw
E
, Aracil
J
, Velard
ME
, Pardhanani
G
, Hepp
Z
. Economic impact of onabotulinumtoxinA for overactive bladder with urinary incontinence in Europe
. J Med Econ
. 2016
;19
(12
):1107
–15
. 7.
Peyronnet
B
, Mironska
E
, Chapple
C
, Cardozo
L
, Oelke
M
, Dmochowski
R
, et al. A comprehensive review of overactive bladder pathophysiology: on the way to tailored treatment
. Eur Urol
. 2019
;75
(6
):988
–1000
. 8.
Kwon
J
, Kim
DY
, Cho
KJ
, Hashimoto
M
, Matsuoka
K
, Kamijo
T
, et al. Pathophysiology of overactive bladder and pharmacologic treatments including β3-Adrenoceptor agonists -basic research perspectives
. Int Neurourol J
. 2024
;28
(Suppl 1
):12
–33
. 9.
Bunn
F
, Kirby
M
, Pinkney
E
, Cardozo
L
, Chapple
C
, Chester
K
, et al. Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies
. Int J Clin Pract
. 2015
;69
(2
):199
–217
. 10.
Kirby
MG
, Wagg
A
, Cardozo
L
, Chapple
C
, Castro-Diaz
D
, de Ridder
D
, et al. Overactive bladder: is there a link to the metabolic syndrome in men
. Neurourol Urodyn
. 2010
;29
(8
):1360
–4
. 11.
He
Q
, Wang
Z
, Liu
G
, Daneshgari
F
, MacLennan
GT
, Gupta
S
. Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links
. Prostate Cancer Prostatic Dis
. 2016
;19
(1
):7
–13
. 12.
Guerrero-Romero
F
, Simental-Mendía
LE
, González-Ortiz
M
, Martínez-Abundis
E
, Ramos-Zavala
MG
, Hernández-González
SO
, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp
. J Clin Endocrinol Metab
. 2010
;95
(7
):3347
–51
. 13.
Hamedi-Shahraki
S
, Klisic
A
, Amirkhizi
F
, Mercantepe
F
. Association of the triglyceride-glucose index with inflammatory markers and dysregulation of adipokines in patients with metabolic syndrome
. BMC Endocr Disord
. 2026
;26
(1
):44
. 14.
Wang
H
, Yang
M
, Cai
W
, Zeng
H
, Luo
X
, Xu
Z
, et al. C-reactive protein-triglyceride-glucose index versus triglyceride-glucose index in predicting cardiovascular metabolic multimorbidity risk: a cohort study
. PLoS One
. 2026
;21
(2
):e0340098
. 15.
Abrams
P
, Cardozo
L
, Fall
M
, Griffiths
D
, Rosier
P
, Ulmsten
U
, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society
. Neurourology and urodynamics
. 2002
;21
(2
):167
–78
. 16.
Ruan
GT
, Xie
HL
, Zhang
HY
, Liu
CA
, Ge
YZ
, Zhang
Q
, et al. A novel inflammation and insulin resistance related indicator to predict the survival of patients with cancer
. Front Endocrinol
. 2022
;13
:905266
. 17.
Kim
SY
, Bang
W
, Choi
HG
. Analysis of the prevalence and associated factors of overactive bladder in adult Korean men
. PLoS One
. 2017
;12
(4
):e0175641
. 18.
Ikeda
Y
, Nakagawa
H
, Ohmori-Matsuda
K
, Hozawa
A
, Masamune
Y
, Nishino
Y
, et al. Risk factors for overactive bladder in the elderly population: a community-based study with face-to-face interview
. Int J Urol
. 2011
;18
(3
):212
–8
. 19.
McKellar
K
, Bellin
E
, Schoenbaum
E
, Abraham
N
. Prevalence, risk factors, and treatment for overactive bladder in a racially diverse population
. Urology
. 2019
;126
:70
–5
. 20.
Tanti
JF
, Ceppo
F
, Jager
J
, Berthou
F
. Implication of inflammatory signaling pathways in obesity-induced insulin resistance
. Front Endocrinol
. 2012
;3
:181
. 21.
Püschel
GP
, Klauder
J
, Henkel
J
. Macrophages, low-grade inflammation, insulin resistance and hyperinsulinemia: a mutual ambiguous relationship in the development of metabolic diseases
. J Clin Med
. 2022
;11
(15
):4358
. 22.
Zheng
P
, Wang
X
, Ni
J
. Relationship between the systemic immune-inflammatory index and overactive bladder risk: a cross-sectional assessment involving United States Adults
. PLoS One
. 2025
;20
(5
):e0323052
. 23.
Liu
HT
, Shie
JH
, Chen
SH
, Wang
YS
, Kuo
HC
. Differences in mast cell infiltration, E-cadherin, and zonula occludens-1 expression between patients with overactive bladder and interstitial cystitis/bladder pain syndrome
. Urology
. 2012
;80
(1
):225.e13
–225.e18
. 24.
Tyagi
P
, Barclay
D
, Zamora
R
, Yoshimura
N
, Peters
K
, Vodovotz
Y
, et al. Urine cytokines suggest an inflammatory response in the overactive bladder: a pilot study
. Int Urol Nephrol
. 2010
;42
(3
):629
–35
. 25.
Duan
F
, Wu
J
, Chang
J
, Peng
H
, Liu
Z
, Liu
P
, et al. Deciphering endocrine function of adipose tissue and its significant influences in obesity-related diseases caused by its dysfunction
. Differentiation
. 2025
;141
:100832
. 26.
Lee
MJ
, Kim
J
. The pathophysiology of visceral adipose tissues in cardiometabolic diseases
. Biochem Pharmacol
. 2024
;222
:116116
. 27.
Luo
Z
, Wu
A
, Robson
S
, Alper
SL
, Yu
W
. Adiponectin signaling regulates urinary bladder function by blunting smooth muscle purinergic contractility
. JCI insight
. 2025
;10
(4
):e188780
. 28.
de Rijk
MM
, Wyndaele
M
, Charrua
A
, Fry
C
, Abrams
P
, van Koeveringe
GA
, et al. What role does the central nervous system play in refractory LUTS, and what are the therapeutic implications? ICI-RS 2025
. Neurourology and urodynamics
. 2026
;45
(5
):929
–36
. 29.
Steers
WD
: Pathophysiology of overactive bladder and urge urinary incontinence
. Rev Urol
. 2002
, 4
(Suppl 4
):S7
–18
.30.
Patra
PB
, Patra
S
. Research findings on overactive bladder
. Curr Urol
. 2015
;8
(1
):1
–21
. 31.
Smith
AL
. Understanding overactive bladder and urgency incontinence: what does the brain have to do with it
. F1000Res
. 2018
;7
:1869
. © 2026 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2026
You do not currently have access to this content.
